Company / EPS (Diluted)
Atea Pharmaceuticals, Inc. EPS (Diluted) History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.51
FY2022
5-year range
-$1.39 / -$0.51
FY2020-FY2022
Trend
+63.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-0.90 to $-0.51 over the past 2 years.
Based on SEC 10-K filings.
-0.51 in FY2022.
Improved from $-0.90 to $-0.51 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, eps (diluted) increased 63.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$0.51 | +63.3% |
| FY2021 | -$1.39 | -54.4% |
| FY2020 | -$0.90 | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026